期刊文献+

TRAIL及其受体在脑胶质瘤的治疗研究进展 被引量:1

下载PDF
导出
摘要 肿瘤坏死因子相关凋亡诱导配体(tumor necrosis factor-related apoptosis-inducing ligand,TRAIL)具选择性诱导肿瘤细胞凋亡作用。研究发现其死亡受体在多数胶质瘤中表达。近年研究认为TRAIL诱导胶质瘤细胞凋亡作用途径主要有胞外线粒体非依赖性途径和胞内线粒体途径。研究还发现将TRAIL与传统及新兴的多种治疗方式联合治疗胶质瘤可发挥协同作用,基因治疗的发展和给药方式的改进促进了TRAIL及其受体在胶质瘤治疗的作用发挥,使得TRAIL成为胶质瘤联合治疗的一种理想的选择。本文在TRAIL及其受体在胶质瘤的表达,作用机制,治疗方式进展等方面进行探讨并进行展望。
出处 《国际神经病学神经外科学杂志》 2011年第4期385-389,共5页 Journal of International Neurology and Neurosurgery
  • 相关文献

参考文献2

二级参考文献186

  • 1[1]Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687-90.
  • 2[2]Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82.
  • 3[3]Wajant H, Moosmayer D, Wuest T, et al. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001; 20:4101-6.
  • 4[4]Tecchio C, Huber V, Scapini P, et al. IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004;103:3837-44
  • 5[5]Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276:111-3.
  • 6[6]Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. Embo J 1997;16:5386-97.
  • 7[7]MacFarlane M, Ahmad M, Srinivasula SM, et al. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272:25417-20.
  • 8[8]Screaton GR, Mongkolsapaya J, Xu XN, et al. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997; 7:693-6.
  • 9[9]Degli-Esposti MA, Dougall WC, Smolak PJ, et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7:813-20.
  • 10[10]Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186:1165-70.

共引文献47

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部